Latigo Biotherapeutics Ups IPO to 19.2 Million Shares

Dow Jones

08/07

Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece.

The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between $16 and $18 apiece.

Latigo now expects gross proceeds to be $345.6 million.

Underwriters also have a 30-day option to buy up to an additional 2.88 million shares at the same price, minus discounts and commissions.

The company, which develops non-opioid pain medicines, plans to trade on Nasdaq under the symbol LTGO. Trading is set to start Friday, with the offering to close Aug. 10.

It intends to use the proceeds from the offering to advance its clinical pipeline, including its lead product candidate LTG-001.

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2657612453"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657612453\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657612453?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657612453","market":"sh","top_or_hot":-1,"title":"Latigo Biotherapeutics Ups IPO to 19.2 Million Shares","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between $16 and $18 apiece. \n</p>\n<p>\n  Latigo now expects gross proceeds to be $345.6 million. \n</p>\n<p>\n  Underwriters also have a 30-day option to buy up to an additional 2.88 million shares at the same price, minus discounts and commissions. \n</p>\n<p>\n  The company, which develops non-opioid pain medicines, plans to trade on Nasdaq under the symbol LTGO. Trading is set to start Friday, with the offering to close Aug. 10. \n</p>\n<p>\n  It intends to use the proceeds from the offering to advance its clinical pipeline, including its lead product candidate LTG-001. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Latigo Biotherapeutics Ups IPO to 19.2 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLatigo Biotherapeutics Ups IPO to 19.2 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-07 18:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between $16 and $18 apiece. \n</p>\n<p>\n  Latigo now expects gross proceeds to be $345.6 million. \n</p>\n<p>\n  Underwriters also have a 30-day option to buy up to an additional 2.88 million shares at the same price, minus discounts and commissions. \n</p>\n<p>\n  The company, which develops non-opioid pain medicines, plans to trade on Nasdaq under the symbol LTGO. Trading is set to start Friday, with the offering to close Aug. 10. \n</p>\n<p>\n  It intends to use the proceeds from the offering to advance its clinical pipeline, including its lead product candidate LTG-001. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657612453","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657612453","pubTimestamp":1786097820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece.The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","KCE":"SPDR KBW Capital Markets ETF","LTGO":"Latigo Biotherapeutics Inc","FRHC":"Euronext CAC Health Care","REDS":"RPM Republican Senate ETF","BK4127":"投资银行业与经纪业"},"translate_title":"Latigo Biotherapeutics 将 IPO 增至 1,920 万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REDS":1.5,"LTGO":1.5,"IPOS":1.5,"KCE":1.5,"FRHC":1.5},"content_text":"Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece. \n\n\n  The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between $16 and $18 apiece. \n\n\n  Latigo now expects gross proceeds to be $345.6 million. \n\n\n  Underwriters also have a 30-day option to buy up to an additional 2.88 million shares at the same price, minus discounts and commissions. \n\n\n  The company, which develops non-opioid pain medicines, plans to trade on Nasdaq under the symbol LTGO. Trading is set to start Friday, with the offering to close Aug. 10. \n\n\n  It intends to use the proceeds from the offering to advance its clinical pipeline, including its lead product candidate LTG-001.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}